NEWS
Adult Stem Cell cellXpansion™ Technology Licenses Made Available at the Second Annual Stem Cell Summit
12 February 2007
Regenetech Inc., the adult stem cell company which uses NASA-licensed technology, today announces that at the second Annual Stem Cell Summit to be held in San Diego on the 12/13 th of February 2007, it will make its licenses available to stem cell banks for its cellXpansion™ technology, which expands hematopoietic stem cells for autologous use.
Dr. David Bonner, Chief Executive Officer of Regenetech, said: “We believe that the essential barrier to wide-spread medical use of adult stem cells is the lack of convenient and economical therapeutic doses of adult stem cells. We believe that Regenetech’s technology provides the most cost-effective solution to this problem. Through the use of our cellXpansion™ system, we hope to make adult stem cell therapy available on a widespread basis.”
In order to encourage broader use of its technology, Regenetech will also make available research licenses at nominal cost to not-for-profit institutions pursuing stem cell research.
Under license from NASA, Regenetech has extended NASA’s patented human progenitor cell technology for use in stem cell banking based on peripheral or umbilical cord blood sources of stem cells.
The second Annual Stem Cell Summit will showcase more than thirty companies as well as physicians and investors who will present and exhibit the latest developments in stem cell products. The summit will also host the first live stem cell surgery in which attendees can ask questions in real-time as surgeons use a stem cell product in the operating room.
For more information about Regenetech and its licensing opportunities, contact Regenetech via e-mail at regenetech@regenetech.com or call Ron Clark at (281) 358-3955. For more information about the 2nd Annual Stem Cell Summit, visit www.stemcellsummit.com.
For further information:
Regenetech, Inc. |
|
Dr. David Bonner, Chief Executive Officer |
Tel: 00 1 713 212 0671 |
|
Media enquiries:
Abchurch |
|
Franziska Böhnke / Joanne Shears |
Tel: +44 (0) 20 7398 7709 |
Notes to Editors:
Regenetech is a leading adult stem cell company that uses NASA licensed technology to expand adult stem cells in a simulated weightless three-dimensional environment. The stem cells are taken from the patient’s peripheral blood and expanded before re-introducing them back into the original patient. The Bioreactor maintains cell-to-cell geometry and communication throughout the expansion process, which leads to more robust expansion of the required stem cells. The Company’s technologies provide the opportunity to treat serious diseases such as diabetes, heart disease and stroke; there are at least 300 million people in the US, EU and Japan who could potentially benefit from stem cell therapeutics now in development.
Regenetech has a series of agreements with prestigious universities in order to further refine its technologies and to develop potential treatments for diabetes and bone/cartilage repair. In addition, its technology is being used in trials in the field of veterinary orthopaedics, whereby the Time Varying Electro-Magnetic Field TM, licensed from NASA, assists in the repair of broken bones in animals.
The Company has a dual track revenue strategy in order to maintain a balance between short and medium term earnings. The Company licenses out technologies for treatments, as well as progressing therapies through the usual biologics clinical trials cycle, which is significantly shorter and less costly than the conventional drugs’ clinical trials process.